<!DOCTYPE html>
<html lang="zh">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Impact of ovarian function suppression on prognosis in premenopausal patientswith HR+/HER2 + early-stage breast cancer: a multi-center retrospective study -PMC</title>
  <style>
    body {
      font-family: "Helvetica Neue", "Noto Sans TC", sans-serif;
      max-width: 720px;
      margin: 2em auto;
      padding: 0 1em;
      color: #333;
      line-height: 1.8;
      background: #fff;
    }
    h1, h2, h3 {
      text-align: center;
      color: #222;
    }
    .lang-switcher {
      text-align: center;
      margin-bottom: 2em;
    }
    .lang-btn {
      margin: 0 0.5em;
      padding: 0.4em 1em;
      border: none;
      background-color: #eee;
      border-radius: 4px;
      cursor: pointer;
      font-weight: bold;
    }
    .lang-btn.active {
      background-color: #007acc;
      color: white;
    }
    ul {
      padding-left: 1.2em;
    }
    a {
      color: #007acc;
      text-decoration: none;
    }
    a:hover {
      text-decoration: underline;
    }
    img {
      max-width: 100%;
      height: auto;
    }
    .share-block {
      text-align: center;
      margin: 1em 0 2em;
      font-size: 0.95em;
    }
    .share-block a svg {
      width: 24px;
      height: 24px;
      display: inline-block;
      vertical-align: middle;
      margin: 0 0.4em;
      transition: transform 0.2s ease;
      cursor: pointer;
    }
    .share-block a svg:hover {
      transform: scale(1.2);
    }
  </style>
</head>
<body>
  <h1>Impact of ovarian function suppression on prognosis in premenopausal patientswith HR+/HER2 + early-stage breast cancer: a multi-center retrospective study -PMC</h1>
  
  <div class="share-block">
    <span>ğŸ”— åˆ†äº«é€™ç¯‡SEOï¼š</span>
    <a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Fimpact-of-ovarian-function-suppression-on-prognosis-in-premenopausal-patientswith-hrher2-earlystage-breast-cancer-a-multicenter-retrospective-study-pmc-seo.html" target="_blank" title="Facebook">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--!Font Awesome Free 6.7.2 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free Copyright 2025 Fonticons, Inc.--><path d="M512 256C512 114.6 397.4 0 256 0S0 114.6 0 256C0 376 82.7 476.8 194.2 504.5V334.2H141.4V256h52.8V222.3c0-87.1 39.4-127.5 125-127.5c16.2 0 44.2 3.2 55.7 6.4V172c-6-.6-16.5-1-29.6-1c-42 0-58.2 15.9-58.2 57.2V256h83.6l-14.4 78.2H287V510.1C413.8 494.8 512 386.9 512 256h0z"/></svg>
    </a>
    <a href="https://x.com/intent/tweet?url=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Fimpact-of-ovarian-function-suppression-on-prognosis-in-premenopausal-patientswith-hrher2-earlystage-breast-cancer-a-multicenter-retrospective-study-pmc-seo.html&text=Impact%20of%20ovarian%20function%20suppression%20on%20prognosis%20in%20premenopausal%20patientswith%20HR%2B%2FHER2%20%2B%20early-stage%20breast%20cancer%3A%20a%20multi-center%20retrospective%20study%20-PMC" target="_blank" title="X">
      <svg xmlns="http://www.w3.org/2000/svg" x="0px" y="0px" width="100" height="100" viewBox="0 0 50 50">
<path d="M 11 4 C 7.134 4 4 7.134 4 11 L 4 39 C 4 42.866 7.134 46 11 46 L 39 46 C 42.866 46 46 42.866 46 39 L 46 11 C 46 7.134 42.866 4 39 4 L 11 4 z M 13.085938 13 L 21.023438 13 L 26.660156 21.009766 L 33.5 13 L 36 13 L 27.789062 22.613281 L 37.914062 37 L 29.978516 37 L 23.4375 27.707031 L 15.5 37 L 13 37 L 22.308594 26.103516 L 13.085938 13 z M 16.914062 15 L 31.021484 35 L 34.085938 35 L 19.978516 15 L 16.914062 15 z"></path></svg>
    </a>
    <a href="https://www.threads.net/intent/post?url=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Fimpact-of-ovarian-function-suppression-on-prognosis-in-premenopausal-patientswith-hrher2-earlystage-breast-cancer-a-multicenter-retrospective-study-pmc-seo.html&text=Impact%20of%20ovarian%20function%20suppression%20on%20prognosis%20in%20premenopausal%20patientswith%20HR%2B%2FHER2%20%2B%20early-stage%20breast%20cancer%3A%20a%20multi-center%20retrospective%20study%20-PMC" target="_blank" title="Threads">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><!--!Font Awesome Free 6.7.2 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free Copyright 2025 Fonticons, Inc.--><path d="M64 32C28.7 32 0 60.7 0 96V416c0 35.3 28.7 64 64 64H384c35.3 0 64-28.7 64-64V96c0-35.3-28.7-64-64-64H64zM294.2 244.3c19.5 9.3 33.7 23.5 41.2 40.9c10.4 24.3 11.4 63.9-20.2 95.4c-24.2 24.1-53.5 35-95.1 35.3h-.2c-46.8-.3-82.8-16.1-106.9-46.8C91.5 341.8 80.4 303.7 80 256v-.1-.1c.4-47.7 11.5-85.7 33-113.1c24.2-30.7 60.2-46.5 106.9-46.8h.2c46.9 .3 83.3 16 108.2 46.6c12.3 15.1 21.3 33.3 27 54.4l-26.9 7.2c-4.7-17.2-11.9-31.9-21.4-43.6c-19.4-23.9-48.7-36.1-87-36.4c-38 .3-66.8 12.5-85.5 36.2c-17.5 22.3-26.6 54.4-26.9 95.5c.3 41.1 9.4 73.3 26.9 95.5c18.7 23.8 47.4 36 85.5 36.2c34.3-.3 56.9-8.4 75.8-27.3c21.5-21.5 21.1-47.9 14.2-64c-4-9.4-11.4-17.3-21.3-23.3c-2.4 18-7.9 32.2-16.5 43.2c-11.4 14.5-27.7 22.4-48.4 23.5c-15.7 .9-30.8-2.9-42.6-10.7c-13.9-9.2-22-23.2-22.9-39.5c-1.7-32.2 23.8-55.3 63.5-57.6c14.1-.8 27.3-.2 39.5 1.9c-1.6-9.9-4.9-17.7-9.8-23.4c-6.7-7.8-17.1-11.8-30.8-11.9h-.4c-11 0-26 3.1-35.6 17.6l-23-15.8c12.8-19.4 33.6-30.1 58.5-30.1h.6c41.8 .3 66.6 26.3 69.1 71.8c1.4 .6 2.8 1.2 4.2 1.9l.1 .5zm-71.8 67.5c17-.9 36.4-7.6 39.7-48.8c-8.8-1.9-18.6-2.9-29-2.9c-3.2 0-6.4 .1-9.6 .3c-28.6 1.6-38.1 15.5-37.4 27.9c.9 16.7 19 24.5 36.4 23.6l-.1-.1z"/></svg>
    </a>
  </div>

  
  <div style="text-align: center;">
    <img src="https://i.imgur.com/H4JFuyI.png" alt="SEO Cover Image" style="max-width: 100%; height: auto; border-radius: 12px; margin-bottom: 1.5em;">
  </div>

  <div class="lang-switcher">
    <button class="lang-btn active" data-lang="zh">ä¸­æ–‡</button><button class="lang-btn " data-lang="en">English</button><button class="lang-btn " data-lang="jp">æ—¥æœ¬èª</button>
  </div>
  
  <div class="ads-block" style="margin: 2.5em 0; position: relative; text-align: center;">
    <a href="https://cancerfree.io/" target="_blank" style="display: inline-block; position: relative;">
      <img src="https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcQI9CDgh7JwzUGH4QTfT5Su2MGI3gUURdf3Tw&s" alt="Advertisement" style="width: 100%; border-radius: 12px; box-shadow: 0 2px 6px rgba(0,0,0,0.1);">
      <div style="
        position: absolute;
        top: 8px;
        right: 8px;
        background: rgba(0, 0, 0, 0.6);
        color: white;
        font-size: 0.75rem;
        padding: 2px 6px;
        border-radius: 4px;
        font-weight: bold;
        letter-spacing: 0.5px;
      ">
        å»£å‘Š
      </div>
    </a>
  </div>
  
  <div class="lang-content" data-lang="zh" style=""><!DOCTYPE html>
<html lang="zh-TW">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>2025 å¹´ä¹³ç™Œæ²»ç™‚æ–°è¶¨å‹¢ï¼šå€‹äººåŒ–è·çˆ¾è’™ç™‚æ³•èˆ‡åµå·¢åŠŸèƒ½æŠ‘åˆ¶çš„ç²¾æº–ç­–ç•¥</title>
    <meta name="description" content="æ·±å…¥æ¢è¨2025å¹´ä¹³ç™Œæ²»ç™‚çš„æœ€æ–°è¶¨å‹¢ï¼Œèšç„¦æ–¼å€‹äººåŒ–è·çˆ¾è’™ç™‚æ³•èˆ‡åµå·¢åŠŸèƒ½æŠ‘åˆ¶çš„ç²¾æº–ç­–ç•¥ï¼ŒåŠ©æ‚¨äº†è§£æœ€æ–°çš„ç ”ç©¶æˆæœèˆ‡æ²»ç™‚é¸æ“‡ã€‚">
    <style>
        body { font-family: sans-serif; line-height: 1.6; }
        h1, h2, h3 { color: #333; }
        a { color: #007bff; text-decoration: none; }
        a:hover { text-decoration: underline; }
        table { border-collapse: collapse; width: 100%; }
        th, td { border: 1px solid #ddd; padding: 8px; text-align: left; }
        th { background-color: #f2f2f2; }
    </style>
</head>
<body>

    <h1>2025 å¹´ä¹³ç™Œæ²»ç™‚æ–°è¶¨å‹¢ï¼šå€‹äººåŒ–è·çˆ¾è’™ç™‚æ³•èˆ‡åµå·¢åŠŸèƒ½æŠ‘åˆ¶çš„ç²¾æº–ç­–ç•¥</h1>

    <h2 id=toc>ç›®éŒ„</h2>
    <ul>
        <li><a href="#introduction">å°è®€ï¼šå¦³çš„ä¹³ç™Œæ²»ç™‚ï¼Œèƒ½æ›´ç²¾æº–å—ï¼Ÿ</a></li>
        <li><a href="#background">èƒŒæ™¯è§£æï¼šç‚ºä»€éº¼å€‹äººåŒ–æ²»ç™‚å¦‚æ­¤é‡è¦ï¼Ÿ</a></li>
        <li><a href="#highlights">é‡é»è§£è®€ï¼šæœ€æ–°ç ”ç©¶æ­ç¤ºçš„é—œéµç™¼ç¾</a></li>
        <li><a href="#expert-opinion">å°ˆå®¶è§€é»ï¼šå¦‚ä½•ç†è§£é€™äº›ç ”ç©¶æˆæœï¼Ÿ</a></li>
        <li><a href="#conclusion">çµè«–èˆ‡è¡Œå‹•å‘¼ç±²ï¼šç‚ºå¦³çš„å¥åº·åšå‡ºæ˜æ™ºçš„é¸æ“‡</a></li>
    </ul>

    <h2 id=introduction>å°è®€ï¼šå¦³çš„ä¹³ç™Œæ²»ç™‚ï¼Œèƒ½æ›´ç²¾æº–å—ï¼Ÿ</h2>

    <p>æƒ³åƒä¸€ä¸‹ï¼Œå¦³è¢«è¨ºæ–·å‡ºä¹³ç™Œï¼Œé†«ç”Ÿé–‹å‡ºæ²»ç™‚æ–¹æ¡ˆã€‚ä½†å¦³æ˜¯å¦æ›¾æƒ³éï¼Œé€™å€‹æ–¹æ¡ˆæ˜¯å¦å®Œå…¨é©åˆå¦³ï¼Ÿæ¯å€‹äººçš„èº«é«”ç‹€æ³ã€åŸºå› ã€ç”Ÿæ´»ç¿’æ…£éƒ½ä¸åŒï¼Œä¹³ç™Œçš„é¡å‹ä¹Ÿå„ç•°ã€‚è¿‘å¹´ä¾†ï¼Œé†«å­¸ç•Œæ­£æœè‘—æ›´ç²¾æº–çš„æ²»ç™‚æ–¹å‘åŠªåŠ›ï¼Œå¸Œæœ›èƒ½ç‚ºæ¯ä½æ‚£è€…æ‰“é€ æœ€é©åˆçš„æ²»ç™‚è¨ˆç•«ã€‚é€™ç¯‡æ–‡ç« å°‡å¸¶é ˜å¦³äº†è§£æœ€æ–°çš„ç ”ç©¶æˆæœï¼Œç‰¹åˆ¥æ˜¯é—œæ–¼è·çˆ¾è’™ç™‚æ³• (Hormone Therapyï¼Œåˆ©ç”¨è—¥ç‰©é˜»æ–·ä¹³ç™Œç´°èƒç”Ÿé•·) èˆ‡åµå·¢åŠŸèƒ½æŠ‘åˆ¶ (Ovarian Function Suppressionï¼ŒOFSï¼Œæš«æ™‚æˆ–æ°¸ä¹…æ€§åœæ­¢åµå·¢åŠŸèƒ½) çš„æ‡‰ç”¨ï¼Œä»¥åŠå¦‚ä½•è®“å¦³çš„ä¹³ç™Œæ²»ç™‚æ›´æœ‰æ•ˆç‡ã€‚</p>

    <h2 id=background>èƒŒæ™¯è§£æï¼šç‚ºä»€éº¼å€‹äººåŒ–æ²»ç™‚å¦‚æ­¤é‡è¦ï¼Ÿ</h2>

    <p>ä¹³ç™Œä¸¦éå–®ä¸€ç–¾ç—…ï¼Œè€Œæ˜¯åŒ…å«è¨±å¤šä¸åŒäºå‹çš„è¤‡é›œç–¾ç—…ã€‚å…¶ä¸­ï¼Œè·çˆ¾è’™å—é«”é™½æ€§ (HR+)/HER2 é™°æ€§ (HER2-) çš„ä¹³ç™Œä½”äº†ç›¸ç•¶æ¯”ä¾‹ã€‚é€™äº›ä¹³ç™Œç´°èƒæœƒåˆ©ç”¨é«”å…§çš„é›Œæ¿€ç´  (Estrogen) ä¿ƒé€²ç”Ÿé•·ã€‚å› æ­¤ï¼Œè·çˆ¾è’™ç™‚æ³•æ˜¯æ²»ç™‚é€™äº›ä¹³ç™Œçš„é‡è¦æ‰‹æ®µã€‚ç„¶è€Œï¼Œè·çˆ¾è’™ç™‚æ³•ä¸¦éå°æ‰€æœ‰å¥³æ€§éƒ½æœ‰æ•ˆï¼Œè€Œä¸”ä¹Ÿå¯èƒ½å¸¶ä¾†å‰¯ä½œç”¨ã€‚æ­¤å¤–ï¼Œå¹´è¼•å¥³æ€§åœ¨æ¥å—è·çˆ¾è’™ç™‚æ³•æ™‚ï¼Œé‚„éœ€è¦è€ƒæ…®åµå·¢åŠŸèƒ½å—å½±éŸ¿çš„å•é¡Œã€‚</p>

    <p>ç‚ºäº†æ”¹å–„æ²»ç™‚æ•ˆæœï¼Œé†«å­¸ç•Œé–‹å§‹é—œæ³¨å€‹äººåŒ–æ²»ç™‚ã€‚é€™æ„å‘³è‘—ï¼Œé†«ç”Ÿæœƒæ ¹æ“šæ‚£è€…çš„å¹´é½¡ã€ç–¾ç—…éšæ®µã€åŸºå› ã€ç”Ÿæ´»ç¿’æ…£ç­‰å› ç´ ï¼Œåˆ¶å®šæœ€é©åˆçš„æ²»ç™‚æ–¹æ¡ˆã€‚ä¾‹å¦‚ï¼Œå¹´è¼•å¥³æ€§åœ¨æ¥å—è·çˆ¾è’™ç™‚æ³•æ™‚ï¼Œæ˜¯å¦éœ€è¦åŒæ™‚é€²è¡Œåµå·¢åŠŸèƒ½æŠ‘åˆ¶ï¼Œä»¥åŠæŠ‘åˆ¶å¤šä¹…ï¼Œéƒ½å–æ±ºæ–¼å¥¹çš„å…·é«”æƒ…æ³ã€‚</p>

    <table>
        <caption>ç›¸é—œç ”ç©¶èˆ‡æœƒè­°</caption>
        <thead>
            <tr>
                <th>ç ”ç©¶/æœƒè­°</th>
                <th>å¹´ä»½</th>
                <th>ä¸»è¦å…§å®¹</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>Ju et al.</td>
                <td>2024</td>
                <td>ç ”ç©¶äº†æ¥å—èµ«è³½æ³° (Trastuzumab) çš„å¹´è¼•å¥³æ€§ä¸­ï¼Œåµå·¢åŠŸèƒ½æŠ‘åˆ¶çš„å½±éŸ¿èˆ‡é æ¸¬å› å­ã€‚</td>
            </tr>
            <tr>
                <td>Sukumar et al.</td>
                <td>2024</td>
                <td>åˆ†æäº†å¹´è¼•å¥³æ€§æ¥å—è·çˆ¾è’™ç™‚æ³•èˆ‡åµå·¢åŠŸèƒ½æŠ‘åˆ¶çš„æ²»ç™‚æ¨¡å¼ã€‚</td>
            </tr>
            <tr>
                <td>Lian et al.</td>
                <td>2017</td>
                <td>ç ”ç©¶äº†å¹´è¼•å¥³æ€§çš„ä¹³ç™Œäºå‹èˆ‡é å¾Œã€‚</td>
            </tr>
            <tr>
                <td>Thomssen et al.</td>
                <td>2021</td>
                <td>è–åŠ ä¾–-ç¶­ä¹Ÿç´æœƒè­°çš„å…±è­˜è¨è«–ï¼Œé—œæ–¼å€‹äººåŒ–æ—©æœŸä¹³ç™Œæ²»ç™‚æ–¹æ¡ˆã€‚</td>
            </tr>
            <tr>
                <td>Francis et al.</td>
                <td>2018</td>
                <td>ã€Šæ–°è‹±æ ¼è˜­é†«å­¸é›œèªŒã€‹ç ”ç©¶ï¼Œæ¢è¨å¹´è¼•å¥³æ€§è·çˆ¾è’™ç™‚æ³•æ–¹æ¡ˆçš„å€‹äººåŒ–ã€‚</td>
            </tr>
            <tr>
                <td>Regan et al.</td>
                <td>2016</td>
                <td>åˆ†æäº†è·çˆ¾è’™ç™‚æ³•å°å¹´è¼•å¥³æ€§çš„ç›Šè™•ï¼Œåƒè€ƒäº† TEXT å’Œ SOFT è©¦é©—çš„æ•¸æ“šã€‚</td>
            </tr>
        </tbody>
    </table>

    <h2 id=highlights>é‡é»è§£è®€ï¼šæœ€æ–°ç ”ç©¶æ­ç¤ºçš„é—œéµç™¼ç¾</h2>

    <p>æœ€æ–°çš„ç ”ç©¶é¡¯ç¤ºï¼Œåµå·¢åŠŸèƒ½æŠ‘åˆ¶å¯ä»¥æé«˜è·çˆ¾è’™ç™‚æ³•çš„æ•ˆæœï¼Œç‰¹åˆ¥æ˜¯åœ¨å¹´è¼•å¥³æ€§ä¸­ã€‚ç„¶è€Œï¼Œåµå·¢åŠŸèƒ½æŠ‘åˆ¶ä¹Ÿå¯èƒ½å¸¶ä¾†å‰¯ä½œç”¨ï¼Œä¾‹å¦‚æ›´å¹´æœŸç—‡ç‹€å’Œç”Ÿè‚²èƒ½åŠ›å—æã€‚å› æ­¤ï¼Œé†«ç”Ÿéœ€è¦ä»”ç´°è©•ä¼°æ‚£è€…çš„å…·é«”æƒ…æ³ï¼Œæ‰èƒ½æ±ºå®šæ˜¯å¦éœ€è¦é€²è¡Œåµå·¢åŠŸèƒ½æŠ‘åˆ¶ï¼Œä»¥åŠæŠ‘åˆ¶å¤šä¹…ã€‚</p>

    <p>æ­¤å¤–ï¼Œç ”ç©¶ä¹Ÿé¡¯ç¤ºï¼Œå¹´è¼•å¥³æ€§çš„ä¹³ç™Œäºå‹èˆ‡é å¾Œæœ‰é—œã€‚ä¾‹å¦‚ï¼ŒæŸäº›äºå‹çš„ä¹³ç™Œæ›´å®¹æ˜“è½‰ç§»åˆ°å…¶ä»–éƒ¨ä½ï¼Œéœ€è¦æ›´ç©æ¥µçš„æ²»ç™‚ã€‚</p>

    <table>
        <caption>å€‹äººåŒ–è·çˆ¾è’™ç™‚æ³•èˆ‡åµå·¢åŠŸèƒ½æŠ‘åˆ¶çš„è€ƒé‡</caption>
        <thead>
            <tr>
                <th>è€ƒé‡å› ç´ </th>
                <th>èªªæ˜</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>å¹´é½¡</td>
                <td>å¹´è¼•å¥³æ€§åœ¨æ¥å—è·çˆ¾è’™ç™‚æ³•æ™‚ï¼Œéœ€è¦è€ƒæ…®åµå·¢åŠŸèƒ½å—å½±éŸ¿çš„å•é¡Œã€‚</td>
            </tr>
            <tr>
                <td>ç–¾ç—…éšæ®µ</td>
                <td>ç–¾ç—…éšæ®µè¶Šæ™šï¼Œè¶Šéœ€è¦ç©æ¥µçš„æ²»ç™‚ã€‚</td>
            </tr>
            <tr>
                <td>ä¹³ç™Œäºå‹</td>
                <td>ä¸åŒçš„ä¹³ç™Œäºå‹ï¼Œéœ€è¦ä¸åŒçš„æ²»ç™‚æ–¹æ¡ˆã€‚</td>
            </tr>
            <tr>
                <td>åŸºå› </td>
                <td>æŸäº›åŸºå› å¯èƒ½å½±éŸ¿è·çˆ¾è’™ç™‚æ³•çš„æ•ˆæœã€‚</td>
            </tr>
        </tbody>
    </table>

    <h2 id=expert-opinion>å°ˆå®¶è§€é»ï¼šå¦‚ä½•ç†è§£é€™äº›ç ”ç©¶æˆæœï¼Ÿ</h2>

    <p>å°ˆå®¶æŒ‡å‡ºï¼Œé€™äº›ç ”ç©¶æˆæœè¡¨æ˜ï¼Œå€‹äººåŒ–æ²»ç™‚æ˜¯æœªä¾†ä¹³ç™Œæ²»ç™‚çš„è¶¨å‹¢ã€‚é†«ç”Ÿéœ€è¦æ ¹æ“šæ‚£è€…çš„å…·é«”æƒ…æ³ï¼Œåˆ¶å®šæœ€é©åˆçš„æ²»ç™‚æ–¹æ¡ˆã€‚æ‚£è€…ä¹Ÿæ‡‰è©²ç©æ¥µåƒèˆ‡æ²»ç™‚æ±ºç­–ï¼Œèˆ‡é†«ç”Ÿå……åˆ†æºé€šï¼Œäº†è§£æ²»ç™‚æ–¹æ¡ˆçš„å„ªç¼ºé»ã€‚</p>

    <p>ç„¶è€Œï¼Œé€™äº›ç ”ç©¶ä¹Ÿå­˜åœ¨ä¸€äº›å±€é™æ€§ã€‚ä¾‹å¦‚ï¼Œç ”ç©¶æ¨£æœ¬é‡å¯èƒ½ä¸è¶³ï¼Œæˆ–è€…ç ”ç©¶çµæœå¯èƒ½ç„¡æ³•å®Œå…¨æ‡‰ç”¨æ–¼æ‰€æœ‰æ‚£è€…ã€‚å› æ­¤ï¼Œæ‚£è€…åœ¨åƒè€ƒé€™äº›ç ”ç©¶æˆæœæ™‚ï¼Œéœ€è¦è¬¹æ…ï¼Œä¸¦èˆ‡é†«ç”Ÿå……åˆ†æºé€šã€‚</p>

    <p><b>æ€è€ƒå•é¡Œï¼š</b>å¦³çš„é†«ç”Ÿæœƒå¦‚ä½•æ ¹æ“šå¦³çš„å…·é«”æƒ…æ³ï¼Œåˆ¶å®šæœ€é©åˆå¦³çš„æ²»ç™‚æ–¹æ¡ˆï¼Ÿå¦³æ˜¯å¦äº†è§£æ²»ç™‚æ–¹æ¡ˆçš„å„ªç¼ºé»ï¼Ÿ</p>

    <h2 id=conclusion>çµè«–èˆ‡è¡Œå‹•å‘¼ç±²</h2>

    <p>2025 å¹´ï¼Œä¹³ç™Œæ²»ç™‚å°‡æ›´åŠ ç²¾æº–ï¼Œå€‹äººåŒ–æ²»ç™‚å°‡æˆç‚ºä¸»æµã€‚è·çˆ¾è’™ç™‚æ³•èˆ‡åµå·¢åŠŸèƒ½æŠ‘åˆ¶çš„æ‡‰ç”¨ï¼Œå°‡æ ¹æ“šæ‚£è€…çš„å…·é«”æƒ…æ³é€²è¡Œèª¿æ•´ã€‚æ‚£è€…éœ€è¦ç©æ¥µåƒèˆ‡æ²»ç™‚æ±ºç­–ï¼Œèˆ‡é†«ç”Ÿå……åˆ†æºé€šï¼Œäº†è§£æ²»ç™‚æ–¹æ¡ˆçš„å„ªç¼ºé»ã€‚ </p>

    <p><b>è¡Œå‹•å‘¼ç±²ï¼š</b></p>
    <ul>
        <li>èˆ‡æ‚¨çš„é†«ç”Ÿè¨è«–æ‚¨çš„æ²»ç™‚æ–¹æ¡ˆï¼Œäº†è§£å…¶å„ªç¼ºé»ã€‚</li>
        <li>ç©æ¥µåƒèˆ‡æ²»ç™‚æ±ºç­–ï¼Œæå‡ºæ‚¨çš„ç–‘å•å’Œæƒ³æ³•ã€‚</li>
        <li>æŒçºŒé—œæ³¨æœ€æ–°çš„ç ”ç©¶æˆæœï¼Œäº†è§£ä¹³ç™Œæ²»ç™‚çš„æœ€æ–°é€²å±•ã€‚</li>
    </ul>

    <p><b>åŸæ–‡è«–æ–‡é€£çµï¼š</b><a href="https://pmc.ncbi.nlm.nih.gov/articles/12359915/">https://pmc.ncbi.nlm.nih.gov/articles/12359915/</a></p>

</body>
</html></div><div class="lang-content" data-lang="en" style="display: none;"><!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Personalized Breast Cancer Treatment Gains Momentum in 2025</title>
    <meta name="description" content="New research highlights the increasing focus on personalized treatment plans for early-stage breast cancer, emphasizing tailored therapies and ovarian suppression. Learn about the latest findings and data insights.">
    <meta name="keywords" content="breast cancer, personalized treatment, ovarian suppression, endocrine therapy, prognosis, early breast cancer, data availability, 2025">
</head>
<body>

    <h1>Personalized Breast Cancer Treatment Gains Momentum in 2025</h1>

    <h2 id="toc">Table of Contents</h2>
    <ul>
        <li><a href="#introduction">Introduction</a></li>
        <li><a href="#background">Background: The Evolution of Breast Cancer Treatment</a></li>
        <li><a href="#highlights">Key Takeaways: What the Research Reveals</a></li>
        <li><a href="#expert-opinion">Expert Opinion: Reflecting on the Future of Care</a></li>
        <li><a href="#conclusion">Conclusion & Call to Action: Staying Informed and Engaged</a></li>
    </ul>

    <h2 id="introduction">Introduction: A New Era in Breast Cancer Care</h2>

    Imagine a future where cancer treatment isn't a one-size-fits-all approach, but a carefully crafted plan tailored to your individual needs. That future is rapidly approaching, particularly in the realm of early-stage breast cancer. Recent research and evolving clinical practices are increasingly focused on personalized treatment strategies, moving beyond standard protocols to consider factors like age, hormone receptor status, and individual risk profiles. This shift promises more effective outcomes and potentially fewer side effects for women facing this challenging diagnosis.  This article explores the latest findings and the ongoing effort to refine these personalized approaches, offering a glimpse into the landscape of breast cancer care in 2025.

    <h2 id=background>Background: The Evolution of Breast Cancer Treatment</h2>

    For decades, breast cancer treatment has relied on a combination of surgery, chemotherapy (drugs that kill rapidly dividing cells), and hormone therapy (endocrine therapy) to block the effects of hormones that fuel cancer growth. However, recognizing that breast cancer isn't a single disease, clinicians have increasingly sought ways to refine treatment based on the specific characteristics of each patient's tumor.

    The concept of personalized medicine has gained traction as researchers have identified various subtypes of breast cancer, each responding differently to various therapies.  Factors like hormone receptor status (whether the cancer cells have estrogen and progesterone receptors) and HER2 status (whether the cancer cells overproduce the HER2 protein) are now routinely assessed to guide treatment decisions.  Furthermore, the impact of age and menopausal status (whether a woman has stopped having menstrual periods) are also being carefully considered.

    <table border="1">
        <caption>Key Factors Influencing Breast Cancer Treatment Decisions</caption>
        <thead>
            <tr>
                <th>Factor</th>
                <th>Description</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>Hormone Receptor Status (ER/PR)</td>
                <td>Indicates whether the cancer cells are fueled by estrogen (ER) or progesterone (PR).</td>
            </tr>
            <tr>
                <td>HER2 Status</td>
                <td>Indicates whether the cancer cells overproduce the HER2 protein.</td>
            </tr>
            <tr>
                <td>Age</td>
                <td>Can influence treatment response and prognosis.</td>
            </tr>
            <tr>
                <td>Menopausal Status</td>
                <td>Affects the choice of endocrine therapy.</td>
            </tr>
        </tbody>
    </table>

    Several studies have contributed to this evolving understanding. For example, research published in 2017 by Lian et al. (Lian W, Fu F, Lin Y, Lu M, Chen B, Yang P, Zeng B, Huang M, Wang C. The impact of young age for prognosis by subtype in women with early breast cancer. Sci Rep. 2017;7(1):11625.) highlighted the impact of age on prognosis, demonstrating differences in outcomes based on cancer subtype.  Further studies, such as those by Francis et al. (Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Lang I, Gomez HL, Tondini C, Ciruelos E, Burstein HJ, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(12):1223-37.) and Regan et al. (Regan MM, Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Lang I, Gomez HL, Tondini C, Ciruelos E, Burstein HJ, et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptorpositive, human epidermal growth factor receptor 2negative early breast cancer TEXT and SOFT trials. J Clin Oncol. 2016;34(22):2131.) have focused on tailoring endocrine therapy for premenopausal women.  The St. Gallen Consensus (Thomssen C, Balic M, Harbeck N, Gnant M. St. GallenVienna. 2021 A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer. Breast Care. 2021;16(1):35-43.) continues to be a vital resource for clinicians seeking to optimize treatment strategies.

    <h2 id=highlights>Key Takeaways: What the Research Reveals</h2>

    Recent studies are providing valuable insights into the nuances of personalized breast cancer treatment. Here's a breakdown of the key findings:

    *   **Ovarian Function Suppression (OFS):**  For premenopausal women receiving certain therapies, suppressing ovarian function â€“ either through medication or surgery â€“ can improve outcomes.  Research by Ju et al. (Ju J, Gao SL, Wang JY, Sang D, Kang YK, Wang X, Yue J, Shuai Y, Qi YX, Yuan P. Prognostic factors and benefit populations of ovarian function suppression in premenopausal HRHER2 earlystage breast cancer patients who received trastuzumab evidence from a realworld study with longterm followup. Thorac Cancer. 2024;15(4):394-7.) has explored the benefits of OFS in specific patient populations.
    *   **Real-World Treatment Patterns:**  Studies examining real-world treatment patterns, such as the work by Sukumar et al. (Sukumar JS, Sardesai S, Ni A, Williams N, Johnson K, Quiroga D, Ramaswamy B, Wesolowski R, Cherian M, Stover DG, et al. Realworld treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HRHER2 breast cancer. Cancer Med. 2024;13(e7317)), are providing a clearer picture of how these personalized approaches are being implemented in clinical practice.
    <table border="1">
        <caption>Summary of Key Findings (2024-2025)</caption>
        <thead>
            <tr>
                <th>Study</th>
                <th>Key Finding</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>Ju et al. (2024)</td>
                <td>OFS benefits specific premenopausal HRHER2 breast cancer patients.</td>
            </tr>
            <tr>
                <td>Sukumar et al. (2024)</td>
                <td>Provides insights into real-world treatment patterns.</td>
            </tr>
        </tbody>
    </table>

    <h2 id=expert-opinion>Expert Opinion: Reflecting on the Future of Care</h2>

    Imagine a conversation with a leading oncologist in 2025. They might say, "We're moving beyond a 'one-size-fits-all' approach to breast cancer treatment.  The data are increasingly clear: tailoring therapies based on individual patient characteristics â€“ their age, hormone receptor status, and even genetic predispositions â€“ leads to better outcomes and fewer side effects.  However, this requires a collaborative effort between clinicians, researchers, and patients, all working together to understand the complexities of this disease.  The challenge now is to ensure that these personalized approaches are accessible to all women, regardless of their geographic location or socioeconomic status."

    What does this mean for you? It means asking questions, being an active participant in your care, and advocating for the most appropriate treatment plan. It also means recognizing that medical advancements are constantly evolving, and staying informed is crucial.

    <h2 id=conclusion>Conclusion & Call to Action</h2>

    The landscape of breast cancer treatment is undergoing a significant transformation. The focus on personalized medicine, driven by ongoing research and evolving clinical practices, offers hope for improved outcomes and a better quality of life for women facing this diagnosis. While significant progress has been made, challenges remain, including ensuring equitable access to these advanced therapies and continuing to refine our understanding of the disease.

    **Call to Action:**

    *   **Stay Informed:** Continue to follow developments in breast cancer research and treatment.
    *   **Engage in Dialogue:** Discuss your individual risk factors and treatment options with your healthcare provider.
    *   **Support Research:** Consider donating to organizations dedicated to breast cancer research and awareness.

    **Data Availability:** The data supporting all tables and figures in this published article are not publicly available to protect patient privacy but can be accessed from the corresponding author on request.



</body>
</html></div><div class="lang-content" data-lang="jp" style="display: none;"><!DOCTYPE html>
<html lang="ja">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>2025å¹´ã€ä¹³ãŒã‚“æ²»ç™‚ã¯ã©ã“ã¸å‘ã‹ã†ï¼Ÿæœ€æ–°ç ”ç©¶ã‹ã‚‰è¦‹ãˆã‚‹æœªæ¥äºˆæ¸¬ - åŒ»ç™‚ãƒ‹ãƒ¥ãƒ¼ã‚¹</title>
  <meta name="description" content="ä¹³ãŒã‚“æ²»ç™‚ã®æœ€æ–°ç ”ç©¶ã‚’å¾¹åº•è§£èª¬ã€‚æ²»ç™‚ã®å€‹åˆ¥åŒ–ã€è‹¥å¹´å¥³æ€§ã¸ã®å½±éŸ¿ã€ãƒ‡ãƒ¼ã‚¿å…¬é–‹ã®ç¾çŠ¶ãªã©ã€2025å¹´ã‚’è¦‹æ®ãˆãŸæœªæ¥äºˆæ¸¬ã‚’ãŠå±Šã‘ã—ã¾ã™ã€‚">
  <meta name="keywords" content="ä¹³ãŒã‚“, æ²»ç™‚, å€‹åˆ¥åŒ–, è‹¥å¹´å¥³æ€§, ãƒ‡ãƒ¼ã‚¿, ç ”ç©¶, 2025å¹´, åŒ»ç™‚, æœ€æ–°æƒ…å ±">
</head>
<body>

  <h1>2025å¹´ã€ä¹³ãŒã‚“æ²»ç™‚ã¯ã©ã“ã¸å‘ã‹ã†ï¼Ÿæœ€æ–°ç ”ç©¶ã‹ã‚‰è¦‹ãˆã‚‹æœªæ¥äºˆæ¸¬</h1>

  <nav>
    <a href="#introduction">ç›®æ¬¡</a>
  </nav>

  <h2 id=toc>ç›®æ¬¡</h2>
  <ul>
    <li><a href="#introduction">å°å…¥</a></li>
    <li><a href="#background">èƒŒæ™¯</a></li>
    <li><a href="#highlights">ãƒã‚¤ãƒ³ãƒˆè§£èª¬</a></li>
    <li><a href="#expert-opinion">å°‚é–€å®¶ã®æ„è¦‹</a></li>
    <li><a href="#conclusion">çµè«–ã¨è¡Œå‹•å‘¼ã³ã‹ã‘</a></li>
  </ul>

  <h2 id=introduction>å°å…¥ï¼šä¹³ãŒã‚“æ²»ç™‚ã®æœªæ¥ã€è¦‹ãˆã¦ããŸå…†ã—</h2>

  <p>ã€Œã‚‚ã—ã€è‡ªåˆ†ã®å¤§åˆ‡ãªäººãŒä¹³ãŒã‚“ã«ã‹ã‹ã£ã¦ã„ãŸã‚‰â€¦ã€ãã†æ€ã†ã¨ã€èƒ¸ãŒç· ã‚ä»˜ã‘ã‚‰ã‚Œã‚‹ã‚ˆã†ãªæ°—æŒã¡ã«ãªã‚Šã¾ã™ã‚ˆã­ã€‚ä¹³ãŒã‚“æ²»ç™‚ã¯æ—¥ã€…é€²æ­©ã—ã¦ã„ã¾ã™ãŒã€ã¾ã ã¾ã èª²é¡Œã‚‚å¤šãã€æ‚£è€…ã•ã‚“ã‚„ã”å®¶æ—ã«ã¨ã£ã¦ä¸å®‰ãªæ™‚é–“ã‚‚å°‘ãªãã‚ã‚Šã¾ã›ã‚“ã€‚ä»Šå›ã¯ã€æœ€æ–°ã®ç ”ç©¶ã‚’ç´è§£ãã€2025å¹´ã‚’è¦‹æ®ãˆãŸä¹³ãŒã‚“æ²»ç™‚ã®æœªæ¥ã«ã¤ã„ã¦ã€ã‚ã‹ã‚Šã‚„ã™ããŠä¼ãˆã—ã¾ã™ã€‚ã¾ã‚‹ã§æœªæ¥ã®åŒ»ç™‚ã‚’è¦—ãè¦‹ã¦ã„ã‚‹ã‹ã®ã‚ˆã†ãªã€æœ€æ–°æƒ…å ±ã«ã”æœŸå¾…ãã ã•ã„ã€‚</p>

  <h2 id=background>èƒŒæ™¯ï¼šç ”ç©¶ã®ç©ã¿é‡ã­ãŒæœªæ¥ã‚’æ‹“ã</h2>

  <p>ä¹³ãŒã‚“æ²»ç™‚ã¯ã€è¿‘å¹´ã€ç›®è¦šã¾ã—ã„é€²æ­©ã‚’é‚ã’ã¦ã„ã¾ã™ã€‚ãã‚Œã¯ã€æ•°å¤šãã®ç ”ç©¶è€…ãŸã¡ã®åœ°é“ãªåŠªåŠ›ã®ç©ã¿é‡ã­ã«ã‚ˆã‚‹ã‚‚ã®ã§ã™ã€‚ç‰¹ã«æ³¨ç›®ã™ã¹ãã¯ã€æ²»ç™‚ã®å€‹åˆ¥åŒ–ã¨ã„ã†æµã‚Œã§ã™ã€‚æ‚£è€…ã•ã‚“ä¸€äººã²ã¨ã‚Šã®çŠ¶æ…‹ã«åˆã‚ã›ã¦ã€æœ€é©ãªæ²»ç™‚æ³•ã‚’é¸æŠã™ã‚‹ã“ã¨ãŒã€ã‚ˆã‚Šè‰¯ã„çµæœã«ã¤ãªãŒã‚‹ã¨è€ƒãˆã‚‰ã‚Œã¦ã„ã¾ã™ã€‚</p>

  <p>ä¾‹ãˆã°ã€è‹¥å¹´å¥³æ€§ã®ä¹³ãŒã‚“æ²»ç™‚ã«ãŠã„ã¦ã¯ã€ãƒ›ãƒ«ãƒ¢ãƒ³ç™‚æ³•ã‚„åµå·£æ©Ÿèƒ½æŠ‘åˆ¶ã¨ã„ã£ãŸæ²»ç™‚æ³•ãŒç”¨ã„ã‚‰ã‚Œã¾ã™ãŒã€ãã®åŠ¹æœã‚„å½±éŸ¿ã¯ã€å¹´é½¢ã‚„ç—…çŠ¶ã«ã‚ˆã£ã¦å¤§ããç•°ãªã‚Šã¾ã™ã€‚ã“ã‚Œã‚‰ã®æ²»ç™‚æ³•ãŒã€æ‚£è€…ã•ã‚“ã«ã©ã®ã‚ˆã†ãªå½±éŸ¿ã‚’ä¸ãˆã‚‹ã®ã‹ã€ã‚ˆã‚Šæ·±ãç†è§£ã™ã‚‹ã“ã¨ãŒé‡è¦ã§ã™ã€‚</p>

  <table>
    <caption>ä¸»è¦ãªç ”ç©¶è«–æ–‡</caption>
    <thead>
      <tr>
        <th>è«–æ–‡ã‚¿ã‚¤ãƒˆãƒ«</th>
        <th>ç™ºè¡¨å¹´</th>
        <th>ä¸»ãªå†…å®¹</th>
      </tr>
    </thead>
    <tbody>
      <tr>
        <td>St. Gallen Vienna Consensus Discussion</td>
        <td>2021</td>
        <td>ä¹³ãŒã‚“æ²»ç™‚ã®å€‹åˆ¥åŒ–ã«é–¢ã™ã‚‹è­°è«–</td>
      </tr>
      <tr>
        <td>Tailoring adjuvant endocrine therapy for premenopausal breast cancer</td>
        <td>2018</td>
        <td>è‹¥å¹´å¥³æ€§ã®ãƒ›ãƒ«ãƒ¢ãƒ³ç™‚æ³•ã«é–¢ã™ã‚‹ç ”ç©¶</td>
      </tr>
      <tr>
        <td>Prognostic factors and benefit populations of ovarian function suppression</td>
        <td>2024</td>
        <td>åµå·£æ©Ÿèƒ½æŠ‘åˆ¶ã®åŠ¹æœã«é–¢ã™ã‚‹ç ”ç©¶</td>
      </tr>
      <tr>
        <td>Realworld treatment patterns of adjuvant endocrine therapy</td>
        <td>2024</td>
        <td>å®Ÿéš›ã®æ²»ç™‚ãƒ‘ã‚¿ãƒ¼ãƒ³ã«é–¢ã™ã‚‹èª¿æŸ»</td>
      </tr>
      <tr>
        <td>The impact of young age for prognosis by subtype in women with early breast cancer</td>
        <td>2017</td>
        <td>è‹¥å¹´å¥³æ€§ã®ä¹³ãŒã‚“ã‚µãƒ–ã‚¿ã‚¤ãƒ—ã¨äºˆå¾Œã«é–¢ã™ã‚‹ç ”ç©¶</td>
      </tr>
    </tbody>
  </table>

  <p>(æ³¨ï¼šä¸Šè¨˜ã¯ä¸»è¦ãªç ”ç©¶ã®ä¸€éƒ¨ã§ã™ã€‚ä¹³ãŒã‚“æ²»ç™‚ã«é–¢ã™ã‚‹ç ”ç©¶ã¯ã€æ—¥ã€…é€²æ­©ã—ã¦ã„ã¾ã™ã€‚)</p>

  <h2 id=highlights>ãƒã‚¤ãƒ³ãƒˆè§£èª¬ï¼šå°‚é–€ç”¨èªã‚’ã‚ã‹ã‚Šã‚„ã™ã</h2>

  <p>ã“ã“ã§ã€ã„ãã¤ã‹å°‚é–€ç”¨èªã‚’è§£èª¬ã—ã¾ã—ã‚‡ã†ã€‚</p>

  <ul>
    <li><b>ãƒ›ãƒ«ãƒ¢ãƒ³ç™‚æ³•</b>ï¼šå¥³æ€§ãƒ›ãƒ«ãƒ¢ãƒ³ã®åƒãã‚’æŠ‘ãˆã‚‹ã“ã¨ã§ã€ãŒã‚“ç´°èƒã®å¢—æ®–ã‚’æŠ‘åˆ¶ã™ã‚‹æ²»ç™‚æ³•ã§ã™ã€‚</li>
    <li><b>åµå·£æ©Ÿèƒ½æŠ‘åˆ¶</b>ï¼šåµå·£ã®æ©Ÿèƒ½ã‚’ä¸€æ™‚çš„ã«æŠ‘ãˆã‚‹ã“ã¨ã§ã€ãƒ›ãƒ«ãƒ¢ãƒ³ç™‚æ³•ã¨ä¸¦è¡Œã—ã¦è¡Œã†ã“ã¨ãŒã‚ã‚Šã¾ã™ã€‚</li>
    <li><b>ã‚µãƒ–ã‚¿ã‚¤ãƒ—</b>ï¼šä¹³ãŒã‚“ã«ã¯ã€æ§˜ã€…ãªç¨®é¡ï¼ˆã‚µãƒ–ã‚¿ã‚¤ãƒ—ï¼‰ãŒã‚ã‚Šã€ãã‚Œãã‚Œæ²»ç™‚æ³•ã‚„äºˆå¾ŒãŒç•°ãªã‚Šã¾ã™ã€‚</li>
  </ul>

  <p>ã“ã‚Œã‚‰ã®æ²»ç™‚æ³•ã¯ã€æ‚£è€…ã•ã‚“ã®çŠ¶æ…‹ã‚„ç—…çŠ¶ã«ã‚ˆã£ã¦ã€æœ€é©ãªçµ„ã¿åˆã‚ã›ãŒç•°ãªã‚Šã¾ã™ã€‚åŒ»å¸«ã¨ã‚ˆãç›¸è«‡ã—ã€è‡ªåˆ†ã«åˆã£ãŸæ²»ç™‚æ³•ã‚’é¸æŠã™ã‚‹ã“ã¨ãŒé‡è¦ã§ã™ã€‚</p>

  <h2 id=expert-opinion>å°‚é–€å®¶ã®æ„è¦‹ï¼šæœªæ¥ã¸ã®å•ã„ã‹ã‘</h2>

  <p>ã€Œä¹³ãŒã‚“æ²»ç™‚ã¯ã€ä»Šå¾Œã€ã•ã‚‰ã«å€‹åˆ¥åŒ–ãŒé€²ã‚€ã¨è€ƒãˆã‚‰ã‚Œã¾ã™ã€‚æ‚£è€…ã•ã‚“ã®éºä¼å­æƒ…å ±ã‚„ç”Ÿæ´»ç¿’æ…£ãªã©ã‚’è€ƒæ…®ã—ã€ã‚ˆã‚Šæœ€é©ãªæ²»ç™‚æ³•ã‚’é¸æŠã§ãã‚‹ã‚ˆã†ã«ãªã‚‹ã§ã—ã‚‡ã†ã€‚ã—ã‹ã—ã€ãƒ‡ãƒ¼ã‚¿ã®å…¬é–‹ãŒåˆ¶é™ã•ã‚Œã¦ã„ã‚‹ç¾çŠ¶ã‚’ã©ã†æ”¹å–„ã—ã¦ã„ãã‹ãŒã€ä»Šå¾Œã®èª²é¡Œã§ã™ã€‚ã€ï¼ˆæ¨¡æ“¬ã‚³ãƒ¡ãƒ³ãƒˆï¼‰</p>

  <p>ã€Œã‚ãªãŸãªã‚‰ã€ä¹³ãŒã‚“æ²»ç™‚ã®æœªæ¥ã®ãŸã‚ã«ã€ã©ã®ã‚ˆã†ãªã“ã¨ã‚’ææ¡ˆã—ã¾ã™ã‹ï¼Ÿ ãœã²ã€å‘¨ã‚Šã®äººã¨æ„è¦‹äº¤æ›ã—ã¦ã¿ã¦ãã ã•ã„ã€‚ã€</p>

  <h2 id=conclusion>çµè«–ã¨è¡Œå‹•å‘¼ã³ã‹ã‘ï¼šæœªæ¥ã¸ã®ä¸€æ­©</h2>

  <p>ä¹³ãŒã‚“æ²»ç™‚ã¯ã€å¸¸ã«é€²åŒ–ã‚’ç¶šã‘ã¦ã„ã¾ã™ã€‚æœ€æ–°ã®ç ”ç©¶ã‚’ç†è§£ã—ã€ç©æ¥µçš„ã«æ²»ç™‚ã«å–ã‚Šçµ„ã‚€ã“ã¨ãŒã€ã‚ˆã‚Šè‰¯ã„æœªæ¥ã¸ã®ç¬¬ä¸€æ­©ã§ã™ã€‚ãã—ã¦ã€æ‚£è€…ã•ã‚“ã ã‘ã§ãªãã€å®¶æ—ã‚„å‘¨ã‚Šã®äººã€…ã®ã‚µãƒãƒ¼ãƒˆã‚‚ä¸å¯æ¬ ã§ã™ã€‚</p>

  <p>ä»Šå›ã®è¨˜äº‹ãŒã€ä¹³ãŒã‚“æ²»ç™‚ã®æœªæ¥ã«ã¤ã„ã¦è€ƒãˆã‚‹ãã£ã‹ã‘ã¨ãªã‚Œã°å¹¸ã„ã§ã™ã€‚ãœã²ã€å‘¨ã‚Šã®äººã¨æ„è¦‹äº¤æ›ã—ã€ã‚ˆã‚Šè‰¯ã„æœªæ¥ã‚’ç¯‰ã„ã¦ã„ãã¾ã—ã‚‡ã†ã€‚</p>

  <p><b>å‚è€ƒè³‡æ–™ï¼š</b><a href="https://pmc.ncbi.nlm.nih.gov/articles/12359915/">ä¹³ãŒã‚“ã«é–¢ã™ã‚‹ç ”ç©¶è«–æ–‡</a></p>

</body>
</html></div>
  <p style="text-align:center; margin-top: 2em;">
    <a href="https://pmc.ncbi.nlm.nih.gov/articles/12359915/" target="_blank">ğŸ‘‰ æŸ¥çœ‹åŸå§‹æ–°è</a>
  </p>
  <script>
    document.querySelectorAll('.lang-btn').forEach(btn => {
      btn.addEventListener('click', () => {
        const lang = btn.dataset.lang;
        document.querySelectorAll('.lang-btn').forEach(b => b.classList.remove('active'));
        btn.classList.add('active');
        document.querySelectorAll('.lang-content').forEach(div => {
          div.style.display = div.dataset.lang === lang ? '' : 'none';
        });
      });
    });
  </script>
</body>
</html>